A possible explanation is that these earlier studies largely relied on a limited number of ER+ breast cancer cell models (e.g., MCF7 and ZR75-1), which do not fully represent the extent of inter-patient heterogeneity. This evidence concerns the gene ESR1 and breast carcinoma.